StreetInsider.com News Articles

BridgeBio Oncology Therapeutics, In (BBOT) PT Lowered to $15 at Stifel

Wed, 09 Sep 2026 09:28:27 -0400

(Updated - September 9, 2026 9:28 AM EDT)

Stifel analyst Laura Prendergast lowered the price target on BridgeBio Oncology Therapeutics, In (NASDAQ: BBOT) to $15.00 (from $23.00) while maintaining a Buy rating.

The analyst commented, "BBOT announced pipeline reprioritization and provided a clinical update for BBO-8520 (KRAS G12C(ON/OFF) inhibitor) +/- pembro in 2L+ NSCLC (PR & slides). Cash runway into 2028 is unchanged from 2Q26 earnings (note here). We make no change to our Buy rating and lower our Target Price to $15 (previously $23).Pipeline reprioritization - BBOT is now focusing capital on:(1) BBO-8520 + pembrolizumab in 2L+ KRAS G12C inhibitorexperienced NSCLC.

BridgeBio Oncology Therapeutics, In (BBOT) PT Lowered to $15 at Stifel

Wed, 09 Sep 2026 09:28:27 -0400

(Updated - September 9, 2026 9:28 AM EDT)

Stifel analyst Laura Prendergast lowered the price target on BridgeBio Oncology Therapeutics, In (NASDAQ: BBOT) to $15.00 (from $23.00) while maintaining a Buy rating.

BridgeBio Oncology Therapeutics, In (BBOT) PT Lowered to $20 at Canaccord

Wed, 09 Sep 2026 07:11:41 -0400

Canaccord analyst John Newman lowered the price target on BridgeBio Oncology Therapeutics, In (NASDAQ: BBOT) to $20.00 (from $23.00) while maintaining a Buy rating.

BridgeBio Oncology reports new data for KRAS cancer drug BBO-8520

Tue, 08 Sep 2026 16:05:58 -0400

BridgeBio Oncology Therapeutics (Nasdaq: BBOT) released new clinical data for its KRAS^G12C inhibitor BBO-8520, according to a company press release, showing response rates in non-small cell lung cancer (NSCLC) patients.

In the ongoing Phase 1 ONKORAS-101 trial, BBO-8520 combined with pembrolizumab achieved a 75% objective response rate (ORR) at the 500 mg once-daily dose level and a 53% ORR across all dose levels in 17 patients with KRAS^G12C inhibitor-experienced NSCLC. The company reported the safety profile was generally tolerable, with adverse events primarily gastrointestinal in nature.

BBO-8520 monotherapy in inhibitor-naïve NSCLC patients showed a 63% ORR (26 of 41 patients) and a

BridgeBio Oncology reports new data for KRAS cancer drug BBO-8520

Tue, 08 Sep 2026 16:05:58 -0400

BBO-8520 monotherapy in inhibitor-naïve NSCLC patients showed a 63% ORR (26 of 41 patients) and a

BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers

Tue, 08 Sep 2026 16:05:00 -0400

BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRAS^G12C inhibitor-experienced NSCLC patients
BBO-8520 monotherapy continues to show highly competitive ORR in the 2L+ KRAS^G12C inhibitor-naïve NSCLC with ORR of 63% (26/41), disease control rate (DCR) of 100% (41/41) and no grade 3 liver enzyme elevations
BBO-11818 and BBO-10203 combination cohorts enrolling in KRAS-mutant CRC and PDAC
$344.1 million in cash, cash equivalents and marketable securities as of June 30, 2026, provides runway into 2028

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology

BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers

Tue, 08 Sep 2026 16:05:00 -0400

BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRAS^G12C inhibitor-experienced NSCLC patients
BBO-8520 monotherapy continues to show highly competitive ORR in the 2L+ KRAS^G12C inhibitor-naïve NSCLC with ORR of 63% (26/41), disease control rate (DCR) of 100% (41/41) and no grade 3 liver enzyme elevations
BBO-11818 and BBO-10203 combination cohorts enrolling in KRAS-mutant CRC and PDAC
$344.1 million in cash, cash equivalents and marketable securities as of June 30, 2026, provides runway into 2028

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology

BBOT to Participate in Upcoming Investor Healthcare Conferences

Tue, 01 Sep 2026 16:05:00 -0400

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in upcoming investor conferences.

Details of the company’s participation are as follows:

Cantor Global Healthcare Conference 2026
Wednesday, September 9, 2026, at 9:45 a.m. ET

Citi's 2026 Biopharma Back to School Conference
Thursday, September 10, 2026, at 3:00 p.m. ET

Morgan Stanley 24th Annual Global Healthcare Conference
Tuesday, September 15, 2026, at 1:50 p.m. ET

BBOT to Participate in Upcoming Investor Healthcare Conferences

Tue, 01 Sep 2026 16:05:00 -0400

Details of the company’s participation are as follows:

Cantor Global Healthcare Conference 2026
Wednesday, September 9, 2026, at 9:45 a.m. ET

Citi's 2026 Biopharma Back to School Conference
Thursday, September 10, 2026, at 3:00 p.m. ET

Morgan Stanley 24th Annual Global Healthcare Conference
Tuesday, September 15, 2026, at 1:50 p.m. ET

BridgeBio Oncology Therapeutics, In (BBOT) PT Lowered to $25 at JPMorgan

Fri, 14 Aug 2026 09:10:40 -0400

JPMorgan analyst Priyanka Grover lowered the price target on BridgeBio Oncology Therapeutics, In (NASDAQ: BBOT) to $25.00 (from $27.00) while maintaining a Overweight rating.

BridgeBio Oncology Therapeutics, Inc. (BBOT) Misses Q2 EPS by 70468c

Tue, 11 Aug 2026 17:03:47 -0400

BridgeBio Oncology Therapeutics, Inc. (NASDAQ: BBOT) reported Q2 EPS of ($705.20), $704.68 worse than the analyst estimate of ($0.52).

For earnings history and earnings-related data on BridgeBio Oncology Therapeutics, Inc. (BBOT) click here.

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Tue, 11 Aug 2026 16:40:00 -0400

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on August 10, 2026 under BBOT’s 2025 Inducement Plan as a material inducement to the employment of two individuals hired by BBOT in July 2026.

The employees received non-qualified stock options to purchase an aggregate 65,350 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $9.28 per share, the closing price of BBOT’s common stock as reported

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Tue, 11 Aug 2026 16:40:00 -0400

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Tue, 11 Aug 2026 16:40:00 -0400

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Tue, 11 Aug 2026 16:40:00 -0400

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Tue, 11 Aug 2026 16:05:00 -0400

Continued to advance monotherapy and combination cohorts for all clinical programs
Initiated dosing of BBO-11818 in combination with cetuximab and after the end of the quarter, initiated dosing of BBO-11818 in combination with BBO-10203
Presented preclinical data at AACR highlighting the potency and activity of BBO-11818 in KRAS mutant tumor models and the efficacy of BBO-10203 in combination with tucatinib and trastuzumab in HER2amp models
Cash runway expected to fund operations into 2028

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Tue, 11 Aug 2026 16:05:00 -0400

Continued to advance monotherapy and combination cohorts for all clinical programs
Initiated dosing of BBO-11818 in combination with cetuximab and after the end of the quarter, initiated dosing of BBO-11818 in combination with BBO-10203
Presented preclinical data at AACR highlighting the potency and activity of BBO-11818 in KRAS mutant tumor models and the efficacy of BBO-10203 in combination with tucatinib and trastuzumab in HER2amp models
Cash runway expected to fund operations into 2028

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Tue, 11 Aug 2026 16:05:00 -0400

Continued to advance monotherapy and combination cohorts for all clinical programs
Initiated dosing of BBO-11818 in combination with cetuximab and after the end of the quarter, initiated dosing of BBO-11818 in combination with BBO-10203
Presented preclinical data at AACR highlighting the potency and activity of BBO-11818 in KRAS mutant tumor models and the efficacy of BBO-10203 in combination with tucatinib and trastuzumab in HER2amp models
Cash runway expected to fund operations into 2028

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Tue, 11 Aug 2026 16:05:00 -0400

Continued to advance monotherapy and combination cohorts for all clinical programs
Initiated dosing of BBO-11818 in combination with cetuximab and after the end of the quarter, initiated dosing of BBO-11818 in combination with BBO-10203
Presented preclinical data at AACR highlighting the potency and activity of BBO-11818 in KRAS mutant tumor models and the efficacy of BBO-10203 in combination with tucatinib and trastuzumab in HER2amp models
Cash runway expected to fund operations into 2028

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway

JPMorgan Starts BridgeBio Oncology Therapeutics, In (BBOT) at Overweight

Wed, 08 Jul 2026 03:12:42 -0400

JPMorgan analyst Priyanka Grover initiates coverage on BridgeBio Oncology Therapeutics, In (NASDAQ: BBOT) with a Overweight rating and a price target of $27.00.

The analyst comments: “We are initiating coverage of BridgeBio Oncology (BBOT) with an Overweight rating and a December 2027 price target of $27. In our view, BridgeBio Oncology’s differentiated next-generation precision oncology approach targeting the RAS and PI3Kα pathways creates an attractive early entry point as we await additional early-stage data. We have a positive outlook on using specific next-generation ON / OFF inhibitors to target mutant KRAS in both on and off states in cancers, which is

JPMorgan Starts BridgeBio Oncology Therapeutics, In (BBOT) at Overweight

Wed, 08 Jul 2026 03:12:42 -0400

JPMorgan analyst Priyanka Grover initiates coverage on BridgeBio Oncology Therapeutics, In (NASDAQ: BBOT) with a Overweight rating and a price target of $27.00.

Form 4 BridgeBio Oncology Thera For: Jul 01 Filed by: Ben Yong

Mon, 06 Jul 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260706/26736868.html

Form 4 BridgeBio Oncology Thera For: Jul 01 Filed by: Beltran Pedro

Mon, 06 Jul 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260706/26736869.html

Form 4 BridgeBio Oncology Thera For: Jul 01 Filed by: Elmelech Idan

Mon, 06 Jul 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260706/26736872.html

Form 4 BridgeBio Oncology Thera For: Jul 01 Filed by: Cobo Marc

Mon, 06 Jul 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260706/26736875.html